We are excited to announce the successful exit of our portfolio company adivo, which we have supported from the very beginning as one of the first investors.
OCCIDENT invests in the Geneva-based company specializing in the development of novel image guidance systems for ventricular arrhythmias using proton therapy.
Tubulis hase announced a strategic license agreement to develop the next generation of ultra-stable antibody-drug conjugates (ADCs) for the treatment of solid tumors.
Bio-Techne and our portfolio company Lunaphore have partnered to develop a fully automated spatial multiomics workflow for the detection of protein and RNA biomarkers on the same slide.